Colorectal Cancer | Unmet Need | US/EU | 2016
Several therapies are available for treatment of second- and subsequent-line advanced/ metastatic colorectal cancer that have a positive effect of patient survival, but none of them are able to cure the disease. Furthermore, some therapies used are associated with side effects that can significantly decrease patients’ quality of life and can also prevent patients from receiving treatment. Hence, there is an unmet need for novel efficacious therapies with an improved safety and tolerability profile, and this Unmet Need module examines the key drivers of prescribing in this indication and analyses significant commercial opportunities.
Related Market Assessment Reports
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…
Report
Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Access & Reimbursement – Age-Related Macular Degeneration (US)
The U.S. wet AMD market is led by intravitreal therapies such as Eylea, Eylea HD, and Vabysmo, alongside the continued off-label use of compounded Avastin, driven by cost considerations. In…
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more potent biologics and/or…
Report
Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)
Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…
